Fig. 7
From: Mesenchymal stem cell-mediated delivery of therapeutic adenoviral vectors to prostate cancer
Adbic-loaded and CRAd-loaded MSCs-E1s suppress prostate cancer cells. Co-cultivation of Ki-ras cells with CRAd-loaded MSCs or MSCs-E1s and Adbic-loaded MSCs or MSCs-E1s was done. Five days later, MTS assay was performed, which showed that MSCs-E1s modification improved CRAd production (
) as well as enabled amplification of replication-defective Adbic (
) as compared to unmodified MSCs